Viewing Study NCT02402660


Ignite Creation Date: 2025-12-25 @ 2:14 AM
Ignite Modification Date: 2026-01-08 @ 5:07 AM
Study NCT ID: NCT02402660
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2025-04-27
First Post: 2015-03-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Sponsor: Alkeus Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module